Mark S. Levine - Apr 17, 2024 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Eva Renee Barnett, attorney-in-fact for Mark S. Levine
Stock symbol
IMVT
Transactions as of
Apr 17, 2024
Transactions value $
-$285,554
Form type
4
Date filed
4/19/2024, 06:06 PM
Previous filing
Apr 4, 2024
Next filing
Apr 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale -$219K -7.6K -2.13% $28.80 349K Apr 17, 2024 Direct F1, F2
transaction IMVT Common Stock Sale -$66.6K -2.23K -0.64% $29.94 347K Apr 17, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.